tiprankstipranks
Advertisement
Advertisement

FBRX Stock Latest News

Forte Biosciences: Buy Rating Backed by FB102 Pipeline Momentum and Multiple Upcoming Clinical Catalysts
RatingsForte Biosciences: Buy Rating Backed by FB102 Pipeline Momentum and Multiple Upcoming Clinical Catalysts
19d ago
FBRX
Forte Biosciences reports Q1 EPS ($1.24), consensus ($1.16)
PremiumThe Fly
Forte Biosciences reports Q1 EPS ($1.24), consensus ($1.16)
20d ago
FBRX
Forte Biosciences Prices $150 Million Public Offering
PremiumCompany Announcements
Forte Biosciences Prices $150 Million Public Offering
2M ago
8K
FBRX
Forte Biosciences 5.71M share Spot Secondary priced at $26.27
PremiumThe Fly
Forte Biosciences 5.71M share Spot Secondary priced at $26.27
2M ago
FBRX
Forte Biosciences announces common stock offering, no amount given
PremiumThe Fly
Forte Biosciences announces common stock offering, no amount given
2M ago
FBRX
Forte Biosciences reports FY25 EPS ($4.71) vs. ($12.17) last year
PremiumThe FlyForte Biosciences reports FY25 EPS ($4.71) vs. ($12.17) last year
2M ago
FBRX
Is FBRX a Buy, Before Earnings?
Premium
Pre-Earnings
Is FBRX a Buy, Before Earnings?
2M ago
FBRX
Forte Biosciences initiated with an Outperform at Evercore ISI
Premium
The Fly
Forte Biosciences initiated with an Outperform at Evercore ISI
6M ago
FBRX
Forte Biosciences Reports Increased R&D Costs Amid Clinical Progress
PremiumCompany Announcements
Forte Biosciences Reports Increased R&D Costs Amid Clinical Progress
7M ago
FBRX
Forte Biosciences reports Q3 EPS (99c), consensus ($1.07)
PremiumThe Fly
Forte Biosciences reports Q3 EPS (99c), consensus ($1.07)
7M ago
FBRX
Forte Biosciences Inc. Launches Promising Study on Alopecia Areata Treatment
PremiumCompany Announcements
Forte Biosciences Inc. Launches Promising Study on Alopecia Areata Treatment
7M ago
FBRX
Forte Biosciences Advances Celiac Disease Treatment with FB102 Study
PremiumCompany Announcements
Forte Biosciences Advances Celiac Disease Treatment with FB102 Study
7M ago
FBRX
Forte Biosciences’ FB102 Study: A Potential Breakthrough in Vitiligo Treatment
PremiumCompany AnnouncementsForte Biosciences’ FB102 Study: A Potential Breakthrough in Vitiligo Treatment
7M ago
FBRX
Forte Biosciences Reports Q2 2025 Financial Results
Premium
Company Announcements
Forte Biosciences Reports Q2 2025 Financial Results
10M ago
FBRX
Forte Biosciences initiated with a Buy at Guggenheim on FB102 potential
Premium
The Fly
Forte Biosciences initiated with a Buy at Guggenheim on FB102 potential
10M ago
FBRX
Forte Biosciences initiated with a Buy at Guggenheim
PremiumThe Fly
Forte Biosciences initiated with a Buy at Guggenheim
10M ago
FBRX
Forte Biosciences Announces Q2 2025 Results and Trials
PremiumCompany Announcements
Forte Biosciences Announces Q2 2025 Results and Trials
10M ago
8K
FBRX
Forte Biosciences reports Q2 EPS (96c), consensus ($1.11)
PremiumThe Fly
Forte Biosciences reports Q2 EPS (96c), consensus ($1.11)
10M ago
FBRX
Sixteen new option listings on July 23rd
PremiumThe Fly
Sixteen new option listings on July 23rd
10M ago
RAL
SMU
Forte Biosciences Announces Public Offering of Shares
PremiumCompany AnnouncementsForte Biosciences Announces Public Offering of Shares
11M ago
8K
FBRX
Forte Biosciences announces common stock offering, no amount given
Premium
The Fly
Forte Biosciences announces common stock offering, no amount given
11M ago
FBRX
Forte Biosciences Stock (FBRX) Surges 25% on Positive Celiac Disease Trial Data
Premium
Market News
Forte Biosciences Stock (FBRX) Surges 25% on Positive Celiac Disease Trial Data
11M ago
FBRX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >